Table 3.

Physical characterization of SLN after stability studies at 40°C ± 2°C and 75% ± 5% RH.

Physical characterization Parameters	Days	Formulation Code
		GMN-3	SAN-3	GLN-3
Size (nm)	0th	124.2 ± 4.1	137.6 ± 6.23	117 ± 1.7
	30th	126.3 ± 4.6	189.4 ± 5.19	117.8 ± 1.4
	90th	136.8 ± 3.2	198.2 ± 5.64	119 ± 2.6
	180th	154.2 ± 5.4	212.1 ± 4.14	126 ± 3.2
PDI	0th	0.31 ± 0.028	0.40 ± 0.048	0.22 ± 0.028
	30th	0.32 ± 0.021	0.41 ± 0.032	0.22 ± 0.071
	90th	0.38 ± 0.035	0.42 ± 0.059	0.23 ± 0.087
	180th	0.39 ± 0.024	0.49 ± 0.035	0.26 ± 0.045
ζ potential (mV)	0th	−23 ± 3.54	−36 ± 4.15	−15 ± 1.43
	30th	−22 ± 3.76	−34 ± 4.52	−16 ± 1.21
	90th	−23 ± 3.18	−30 ± 4.98	−16 ± 1.76
	180th	−20 ± 4.25	−28 ± 3.17	−18 ± 1.65
Entrapment efficiency (%)	0th	69.96 ± 3.61	59.32 ± 3.59	89.54 ± 1.43
	30th	68.21 ± 4.41	58.87 ± 3.59	89.19 ± 3.32
	90th	67.45 ± 3.13	54.64 ± 3.59	88.34 ± 2.43
	180th	61.18 ± 3.23	46.39 ± 3.59	86.42 ± 1.46
In-vitro % cumulative drug release (in 24 h)	0th	82.07 ± 1.78	88.89 ± 2.34	73.54 ± 1.76
	30th	83.21 ± 1.57	90.48 ± 2.25	74.23 ± 2.23
	90th	85.43 ± 2.32	94.23 ± 2.92	75.12 ± 1.87
	180th	92.45 ± 3.97	96.43 ± 3.54	76.32 ± 2.13

All data expressed as mean ± S.D.; n = 3; P ≤ 0.05.